HETEROCYCLIC COMPOUNDS AS TRK INHIBITORS Russian patent published in 2023 - IPC C07D498/18 C07D498/22 A61K31/519 A61P35/00 

FIELD: pharmaceuticals.

SUBSTANCE: invention relates to a compound of formula I and its pharmaceutically acceptable salts, where L₁ is selected from -NR⁶ CON(R⁷)-, in which NR⁶ is connected to a nitrogen-containing heteroaryl substituted with R¹, R², R³; L₂ is selected from C1-C4alkylene, where the alkylene may be optionally substituted with one or more G1; L₃ is -O-; each R¹, R², R³ is independently selected from hydrogen; R⁴ is selected from hydrogen and halogen; R ⁵ is selected from hydrogen and halogen; each R⁶, R⁷ is independently selected from hydrogen, C1-C4alkyl; G1 is selected from C1-C4alkyl. The invention also relates to a pharmaceutical composition for the treatment or prevention of TRK-mediated diseases, comprising a therapeutically effective amount of a compound of the invention, or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable carriers, diluents, and auxiliaries. The compounds of the invention, or pharmaceutically acceptable salts thereof, or a pharmaceutical composition based on them are used in the preparation of a medicament for the treatment or prevention of TRK-mediated diseases such as cancer, especially hematological malignancies, lung cancer, breast cancer, ovarian cancer, prostate cancer, cancer pancreas and glioma.

EFFECT: using compounds as TRK inhibitors.

4 cl, 1 tbl, 4 ex